A5087692198- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Cancer Genomics and Diagnostics
- Lymphatic Disorders and Treatments
- Integrated Circuits and Semiconductor Failure Analysis
- Autoimmune and Inflammatory Disorders Research
- Advancements in Semiconductor Devices and Circuit Design
- Polyomavirus and related diseases
- Lung Cancer Treatments and Mutations
- COVID-19 Clinical Research Studies
- Biomedical Ethics and Regulation
- Acute Lymphoblastic Leukemia research
- Virus-based gene therapy research
- Hematological disorders and diagnostics
- Clostridium difficile and Clostridium perfringens research
- Vascular Malformations and Hemangiomas
- Psychological Treatments and Assessments
- Intracerebral and Subarachnoid Hemorrhage Research
- Salivary Gland Tumors Diagnosis and Treatment
- Pleural and Pulmonary Diseases
- Immune cells in cancer
- Spinal Hematomas and Complications
- Dermatological and COVID-19 studies
- Parvovirus B19 Infection Studies
King Saud bin Abdulaziz University for Health Sciences
2025
King Abdullah International Medical Research Center
2025
McMaster University
2024-2025
University of Maryland, Baltimore
2019-2023
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
2019-2023
University of Maryland Medical Center
2019-2023
Salford Royal NHS Foundation Trust
2023
Warrington and Halton Teaching Hospitals NHS Foundation Trust
2023
Northern Health and Social Care Trust
2023
University of Manchester
2023
Although the majority of patients with relapsed or refractory large B-cell lymphoma respond to axicabtagene ciloleucel (axi-cel), only a minority have durable remissions. This prospective multicenter study explored prognostic value circulating tumor DNA (ctDNA) before and after standard-of-care axi-cel for predicting patient outcomes.Lymphoma-specific variable, diversity, joining gene segments (VDJ) clonotype ctDNA sequences were frequently monitored via next-generation sequencing from time...
Recent evidence suggests a benefit in platelet-rich plasma injections (PRP) for the knee management of mild to moderate osteoarthritis (OA). There is reported reduction pain, stiffness, and improved function. However, there very little level-one literature available that supports this practice conclusively proves gained throughout course. Three main randomized control trials (RCTs) conducted North America are often referenced cited prove their efficacy. This study aimed look at outcomes...
Summary In the relapsed/refractory setting for treatment of large B‐cell lymphoma (LBCL), chimeric antigen receptor T‐cell (CAR‐T) therapy has emerged as an effective modality. Patients often have aggressive disease that requires prompt in form bridging (BT) stabilisation while CAR‐T cells are manufactured. ( n = 75) undergoing infusion LBCL at our institution were identified. A total 52 (69·3%) received BT and 23 (30·7%) no (NBT). modalities included systemic (SBT) 28 patients, radiation...
Secondary hemophagocytic lymphohistiocytosis (HLH) is a life-threatening immune dysregulation disorder. Use of chimeric antigen receptor T-cell therapy (CAR-T) associated with cytokine release syndrome (CRS), Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) and secondary HLH. However, application HLH scoring systems (H-score, HLH-2004 criteria) are not validated in this setting. We analyzed the utility applying H-score criteria to identify patients possible post-CAR-T for...
CD19 directed CAR-T therapy for Large B-cell lymphoma (LBCL) has shown great therapeutic response in patients with relapsed/refractory disease rates of 60-80%. However, a partial (PR) on initial day 28 post imaging, clinical uncertainty remains as half these will ultimately have relapsed disease. PATIENTS: In 24 receiving LBCL achieving PR 28, we utilize imaging biomarkers by 18F-FDG PET/CT at pre baseline and to determine factors that may predict best overall (B-OR), progression free...
Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a rapidly-advancing treatment modality for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) with response rates approaching 60–80%.1, 2 The registrational clinical trials that lead to the approval of CAR-T in R/R LBCL, well ongoing trials, have excluded patients previous allogeneic haematopoietic cell transplantation (alloHCT) from trial participation.3-8 To date, limited data exists describing safety and efficacy...
Early and uneventful postoperative recovery of morbidly obese patients remains a challenge for anesthesiologists.However, it could be even more valuable to titrate the administration inhaled anesthetic such as sevoflurane in morbid patients, shorten emergence using bispectral index (BIS) monitoring. It would great advantage if BIS permitted rapid less consumption with high cost agent. The aim study is show whether titration based on monitoring allow shortening time evaluate contribute reduce...
Hemophagocytic lymphohistiocytosis (HLH) is a disorder of immune regulation, manifested by fever, pancytopenia, hyperferritiniemia, hypertriglyceridemia, and extensive hemophagocytosis involving the bone marrow spleen. HLH can occur in adults with an underlying hematopoietic malignancy, or systemic infections. following stem cell transplantation (HSCT) unusual, diagnosis may be challenging particularly because diagnostic criteria HLH-2004 guidelines overlap common post-transplant...
Introduction: Blinatumomab, a first-in-class bispecific T cell engager, is member of novel class antibody constructs with dual binding specificities. While its primary clinical use has been in B acute lymphoblastic leukemia, role the treatment non-Hodgkin's Lymphoma (NHL) less well established.Areas covered: Herein, authors provide brief overview market, unmet needs, and how blinatumomab fits to evolving armamentarium lymphoma-directed therapies. The address therapeutic salvage therapy for...
7552 Background: Axicabtagene Ciloleucel (Axi-cel) is an autologous anti-CD19 CAR T-cell therapy approved for the treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Long‐term analysis Zuma‐1 clinical trial showed ~40% patients remained progression-free at 2 years (Locke, Lancet Oncology 2018). Early identification who will later progress after T cell may improve care and patient outcomes. Methods: As 2/1/2019, we enrolled 50 on a multi-institutional, prospective...
Abstract Background Autoimmune Enteropathy is a rare condition characterized by clinical symptoms of intractable diarrhea, vomiting, and weight loss that often results in malnutrition. It associated with other autoimmune conditions from primary sclerosing cholangitis to type 1 diabetes thyroid disease. The epidemiology AIE adults not well described. detailed more the pediatric population, particularly early life, incidence estimated at less than 100,000 infants. Aims Aims: To review case...
7560 Background: Axicabtagene Ciloleucel (Axi-cel), an anti-CD19 CART cell therapy, achieved 58% complete response (CR) rate, in patients with relapsed refractory (r/r) LBCL on the ZUMA-1 study (Neelapu, NEJM 2017). Early assessment (PET-CT) at day 30 is a common clinical practice. Patients partial (PR) pose therapeutic dilemma. analysis showed 1/3rd PR would convert to CR. No biomarkers exist predict eventual response. We report comprehensive PET-CT biomarker treated Axi-cel for r/r LBCL....